Ryanodine Receptors: Current Progress and Future Perspective

Qing       Yang; Zhiguang      Yuchi

doi:10.2174/138161282801211223123314

[1] 
Beaufils M, Travard L, Rendu J, Marty I. Therapies for RYR1-related myopathies: where we stand and the perspectives. Curr Pharm Des  2022; 28(1): 15-25.
[2] 
Kruijt, de Bersselaar V L, Snoeck M et al. RYR1-related rhabdomyolysis: a spectrum of hypermetabolic states due to ryanodine receptor dysfunction. Curr Pharm Des. 2022; 28(1): 2-14.
[3] 
Samurkas Yao L. Hadiatullah H et al Ryanodine receptor as insecticide target. Curr Pharm Des  2022; 28(1): 26-35.

Download Options

Rights & Permissions Print Cite

Current Pharmaceutical Design

Title:Ryanodine Receptors: Current Progress and Future Perspective

Volume: 28 Issue: 1

Author(s): Qing Yang and Zhiguang Yuchi

Affiliation:

Export Options

Export File:

RIS (for EndNote, Reference Manager, ProCite)

BibTeX

Text

Content:

Citation Only

Citation and Abstract

About this article

Cite this article as:

Yang Qing and Yuchi Zhiguang, Ryanodine Receptors: Current Progress and Future Perspective, Current Pharmaceutical Design 2022; 28 (1) . https://dx.doi.org/10.2174/138161282801211223123314

DOI https://dx.doi.org/10.2174/138161282801211223123314	Print ISSN 1381-6128
Publisher Name Bentham Science Publisher	Online ISSN 1873-4286